ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Erdheim-Chester (ECD) Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor ECD.

Literatuur

  1. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126(1): 26-35. doi: 10.1182/blood-2014-12-569301
  2. Allen CE, Merad M, McClain KL. Langerhans cell histiocytosis. The New England journal of medicine 2018; 379(9): 856-868. doi: 10.1056/NEJMra1607548
  3. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127(22): 2672-2681. doi: 10.1182/blood-2016-01-690636
  4. Frater JL. The histiocytoses: as easy as ABC (or LCMRH). Blood 2016; 127(22): 2655-2656. doi: 10.1182/blood-2016-03-706267
  5. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124(4): 483-492. e-pub ahead of print 2014/05/23; doi: 10.1182/blood-2014-03-561381
  6. Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014; 124(7): 1119-1126. e-pub ahead of print 2014/06/05; doi: 10.1182/blood-2013-12-543793
  7. Estrada-Veras JI, O'Brien KJ, Boyd LC, Dave RH, Durham B, Xi L et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 2017; 1(6): 357-366. e-pub ahead of print 2017/05/30; doi: 10.1182/bloodadvances.2016001784
  8. Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 2017; 130(8): 1007-1013. e-pub ahead of print 2017/07/07; doi: 10.1182/blood-2017-01-761718
  9. Goyal G, Heaney ML, Collin M, Cohen Aubart F, Vaglio A, Durham BH et al. Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood 2020. e-pub ahead of print 2020/03/19; doi: 10.1182/blood.2019003507
  10. Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019; 567(7749): 521-524. e-pub ahead of print 2019/03/15; doi: 10.1038/s41586-019-1012-y
  11. Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017; 130(11): 1377-1380. doi: 10.1182/blood-2017-03-771873

 

Ga terug naar de ECD homepage of lees meer over ECD:

Ga terug naar de algemene homepage Behandelprotocollen.